Johnson & Johnson (JNJ) 100.50 $JNJ
Jim Cramer's 'Mad Money' Recap: Bubbles vs. Valuation
at The Street - Thu May 08, 7:22PM CDT
Unlike the dot-com bubble, new companies today can make a profit but choose not to do so, prefering high valuations, Cramer says.
Final Glance: Medical Devices companies
AP - Thu May 08, 5:02PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Thu May 08, 5:02PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
FDA approves Merck blood thinner for some patients
By MATTHEW PERRONE - AP - Thu May 08, 5:00PM CDT
WASHINGTON (AP) — The Food and Drug Administration has approved a new type of blood thinner from Merck that reduces heart attack, stroke and other fatal cardiovascular events in patients with a history of heart attack.
J&J /Gilead HCV Combo Drug Filed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 3:55PM CDT
Johnson & Johnson (JNJ) is seeking to expand the label of Olysio.
Corcept Plunges on Study Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 3:35PM CDT
Shares of Corcept Therapeutics Inc. (CORT) were down 50.5% after the company announced that it will discontinue the study on Korlym (study 14) for the treatment of psychotic depression.
Research and Markets: Xeljanz (Ulcerative Colitis) - Forecast and Market Analysis to 2022:
Business Wire - Thu May 08, 1:34PM CDT
Research and Markets (http://www.researchandmarkets.com/research/vbwk7b/xeljanz) has announced the addition of the "Xeljanz (Ulcerative Colitis) - Forecast and Market Analysis to 2022" report to their offering.
ArQule Posts Narrower-than-Expected Q1 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 12:58PM CDT
ArQule (ARQL) reported a loss of 11 cents per share in the first quarter of 2014, narrower than the Zacks Consensus Estimate of a loss of 12 cents per share.
Midday Glance: Pharmaceuticals companies
AP - Thu May 08, 12:23PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Midday Glance: Medical Devices companies
AP - Thu May 08, 12:23PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
Research and Markets: Uceris (Ulcerative Colitis) - Forecast and Market Analysis to 2022
Business Wire - Thu May 08, 12:12PM CDT
Research and Markets (http://www.researchandmarkets.com/research/f42bmd/uceris) has announced the addition of the "Uceris (Ulcerative Colitis) - Forecast and Market Analysis to 2022" report to their offering.
11.4% Return Seen to Date on SmarTrend Johnson & Johnson Call (JNJ)
Comtex SmarTrend(R) - Thu May 08, 10:05AM CDT
SmarTrend identified an Uptrend for Johnson & Johnson (NYSE:JNJ) on February 10th, 2014 at $90.44. In approximately 3 months, Johnson & Johnson has returned 11.36% as of today's recent price of $100.71.
Early Glance: Pharmaceuticals companies
AP - Thu May 08, 9:48AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Early Glance: Medical Devices companies
AP - Thu May 08, 9:48AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
Xeljanz (Ulcerative Colitis) - Forecast and Market Analysis to 2022:
M2 - Thu May 08, 6:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wbxt4m/xeljanz) has announced the addition of the "Xeljanz (Ulcerative Colitis) - Forecast and Market Analysis to 2022" report to their offering. During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson's (J&J's) Simponi and Takeda's Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively. Pfizer developed Xeljanz (tofacitinib, formerly known as tasocitinib), an oral, small-molecule JAK inhibitor, for the treatment of RA, and as a potential treatment for psoriasis, psoriatic arthritis, ankylosing spondylitis, CD, and UC. Xeljanz is a potential first-in-class product for UC, being one of the most advanced JAK inhibitors in the pipeline. Scope - Overview of Ulcerative Colitis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Xeljanz including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Xeljanz for the top eight countries from 2012 to 2022. - Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Canada. Reasons to buy - Understand and capitalize by identifying products that are most likely to ensure a robust return - Stay ahead of the competition by understanding the changing competitive landscape for Ulcerative Colitis - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential - Make more informed business decisions from insightful and in-depth analysis of Xeljanz performance Key Topics Covered: 1 Table of Contents 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Opportunity and Unmet Need 7 Pipeline Assessment 8 Xeljanz (tofacitinib) 9 Appendix For more information visit http://www.researchandmarkets.com/research/wbxt4m/xeljanz
Janssen Announces Expanded Collaboration with International Partnership for Microbicides for Development and Commercialization of Dapivirine for Prevention of Sexual Transmission of HIV
PR Newswire Europe - Thu May 08, 5:18AM CDT
-- Latest innovative collaboration from the Janssen Global Public Health group and significant contribution to Johnson & Johnson's wider efforts to improve public health worldwide
Johnson & Johnson Is Rewarding but Too Expensive
at The Street - Thu May 08, 5:00AM CDT
The share price may be too high for yield-hungry investors. But that could be changing soon.
Refractory Multiple Myeloma - Pipeline Review, H1 2014: 33 Companies and 48 Drugs Profiled
M2 - Thu May 08, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r636v2/refractory) has announced the addition of the "Refractory Multiple Myeloma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Refractory Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Multiple Myeloma and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Refractory Multiple Myeloma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Refractory Multiple Myeloma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Refractory Multiple Myeloma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved: - AbbVie Inc. - Acceleron Pharma, Inc. - Acetylon Pharmaceuticals, Inc. - Altor BioScience Corporation - Array BioPharma Inc. - Astellas Pharma Inc. - Bristol-Myers Squibb Company - Celgene Corporation - Eli Lilly and Company - Exelixis, Inc. - Genentech, Inc. - GlaxoSmithKline plc - Incyte Corporation - Janssen Biotech, Inc. - Johnson & Johnson - Kyowa Hakko Kirin Co., Ltd. - Millennium Pharmaceuticals, Inc. - MorphoSys AG - Novartis AG - Oncolytics Biotech Inc. - Oncopeptides AB - Onyx Pharmaceuticals, Inc. - Pfizer Inc. - Pharma Mar, S.A. - Pharmacyclics, Inc. - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Sanofi - Senesco Technologies, Inc. - Senhwa Biosciences Drug Profiles: - ixazomib citrate - panobinostat - carfilzomib - elotuzumab - plitidepsin - bendamustine - ibrutinib - ruxolitinib phosphate - ARRY-520 - ALT-801 - pomalidomide - chloroquine [bortezomib] [cyclophosphamide] - Melflufen - Circularly Permuted TRAIL - alisertib - daratumumab - PRLX-93936 - carfilzomib - cabozantinib (s)-malate - SNS-01T - SL-401 - TH-302 - P-276 - MOR-202 - KW-2478 - palbociclib - luminespib - plerixafor - ricolinostat - LY-2812176 For more information visit http://www.researchandmarkets.com/research/r636v2/refractory
Tuberculosis - Pipeline Review, H1 2014: 54 Companies and 141 Drugs Profiled
M2 - Thu May 08, 4:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gtc5l6/tuberculosis) has announced the addition of the "Tuberculosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Tuberculosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tuberculosis and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Tuberculosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Tuberculosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Tuberculosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved: - Abera Bioscience AB - Achillion Pharmaceuticals, Inc. - Anacor Pharmaceuticals, Inc. - Archivel Farma S.L. - AstraZeneca PLC - B&C Biopharm - BioDiem Ltd - Bioversys AG - Canopus BioPharma Incorporated - Cellceutix Corporation - Chimerix, Inc. - Chongqing Zhifei Biological Products Co., Ltd. - Crucell N.V. - Dafra Pharma International Ltd. - Eisai Co., Ltd. - Eli Lilly and Company - Ensoltek Co., Ltd. - EpiVax, Inc. - FIT Biotech Oyj - Genticel - GlaxoSmithKline plc - GlobalAcorn - Globeimmune, Inc. - Imaxio - Immunitor, Inc. - ImmunoBiology Ltd. - Immunovaccine, Inc. - Johnson & Johnson - Lipotek Pty Ltd. - Medisyn Technologies, Inc. Drug Profiles: - delamanid - delamanid - V-7 Vaccine - SQ-109 - delamanid - Tuberculosis Vaccine - sutezolid - VPM-1002 - GSK-692342 - Crucell Ad-35 - RUTI Vaccine - SSI H56-IC31 Vaccine - AERAS-422 Vaccine - IMX-313-TB - Ad5Ag85A Vaccine - PMX-10072 - NasL3/HtkBCG Vaccine - MTBVAC01 - Ac2SGL Diacylated Sulfoglycolipid Vaccine - HG-85A/B - HG856-A - HG856-BCG - R32Kda-BCG Vaccine - AERAS-Capsid Vaccine - HBHA Vaccine - Streptomyces Live Vector Vaccine - rBCG(mbtB)30 Vaccine - NasL3/AM85B Vaccine - paBCG Vaccine - ORT-VAC DNA Vaccine For more information visit http://www.researchandmarkets.com/research/gt...berculosis
Bone Metastasis - Pipeline Review, H1 2014: 20 Companies and 33 Drugs Profiled
M2 - Thu May 08, 3:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7v66kz/bone_metastasis) has announced the addition of the "Bone Metastasis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Metastasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Metastasis and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Bone Metastasis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Bone Metastasis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Bone Metastasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects Companies Involved: - APT Therapeutics, Inc. - Alethia Biotherapeutics Inc. - AlphaMab Co., Ltd - Amgen Inc. - Amura Holdings Ltd. - Bayer AG - Celsion Corporation - Debiopharm International S.A. - Deciphera Pharmaceuticals, LLC - DexTech Medical AB - Digna Biotech, S.L. - Eli Lilly and Company - Johnson & Johnson - Medivir AB - Merrion Pharmaceuticals Plc - Osteologix Holdings Plc. - Sigma-Tau S.p.A. - TWi Pharmaceuticals, Inc. - Takeda Pharmaceutical Company Limited - Transgene SA Drug Profiles: - denosumab - denosumab - radium Ra 223 dichloride - zoledronic acid - MLN-1202 - doxorubicin liposomal - radium Ra 223 dichloride - Osteodex - MIV-711 - Debio-0719 - P-17 - disitertide - MIV-710 - SST-0001 - TG-3003 - AB-25E9 - AM-3701 - DCC-2909 - AC-301 - APT-102 - Secreted Phosphoprotein 24 KDa - Vicrostatin - ADM-01 - JNJ-28312141 - DP-6865 - LY-2109761 - LY-364937 - EGFR Inhibitors for Oncology - (paclitaxel PEG alendronate) For more information visit http://www.researchandmarkets.com/research/7v...metastasis
Jim Cramer's 'Mad Money' Recap: Bubbles vs. Valuation
at The Street - Thu May 08, 7:22PM CDT
Unlike the dot-com bubble, new companies today can make a profit but choose not to do so, prefering high valuations, Cramer says.
Final Glance: Medical Devices companies
AP - Thu May 08, 5:02PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Thu May 08, 5:02PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
FDA approves Merck blood thinner for some patients
By MATTHEW PERRONE - AP - Thu May 08, 5:00PM CDT
WASHINGTON (AP) — The Food and Drug Administration has approved a new type of blood thinner from Merck that reduces heart attack, stroke and other fatal cardiovascular events in patients with a history of heart attack.
J&J /Gilead HCV Combo Drug Filed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 3:55PM CDT
Johnson & Johnson (JNJ) is seeking to expand the label of Olysio.
Corcept Plunges on Study Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 3:35PM CDT
Shares of Corcept Therapeutics Inc. (CORT) were down 50.5% after the company announced that it will discontinue the study on Korlym (study 14) for the treatment of psychotic depression.
Research and Markets: Xeljanz (Ulcerative Colitis) - Forecast and Market Analysis to 2022:
Business Wire - Thu May 08, 1:34PM CDT
Research and Markets (http://www.researchandmarkets.com/research/vbwk7b/xeljanz) has announced the addition of the "Xeljanz (Ulcerative Colitis) - Forecast and Market Analysis to 2022" report to their offering.
ArQule Posts Narrower-than-Expected Q1 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 12:58PM CDT
ArQule (ARQL) reported a loss of 11 cents per share in the first quarter of 2014, narrower than the Zacks Consensus Estimate of a loss of 12 cents per share.
Midday Glance: Pharmaceuticals companies
AP - Thu May 08, 12:23PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Midday Glance: Medical Devices companies
AP - Thu May 08, 12:23PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
Research and Markets: Uceris (Ulcerative Colitis) - Forecast and Market Analysis to 2022
Business Wire - Thu May 08, 12:12PM CDT
Research and Markets (http://www.researchandmarkets.com/research/f42bmd/uceris) has announced the addition of the "Uceris (Ulcerative Colitis) - Forecast and Market Analysis to 2022" report to their offering.
11.4% Return Seen to Date on SmarTrend Johnson & Johnson Call (JNJ)
Comtex SmarTrend(R) - Thu May 08, 10:05AM CDT
SmarTrend identified an Uptrend for Johnson & Johnson (NYSE:JNJ) on February 10th, 2014 at $90.44. In approximately 3 months, Johnson & Johnson has returned 11.36% as of today's recent price of $100.71.
Early Glance: Pharmaceuticals companies
AP - Thu May 08, 9:48AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Early Glance: Medical Devices companies
AP - Thu May 08, 9:48AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
Xeljanz (Ulcerative Colitis) - Forecast and Market Analysis to 2022:
M2 - Thu May 08, 6:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wbxt4m/xeljanz) has announced the addition of the "Xeljanz (Ulcerative Colitis) - Forecast and Market Analysis to 2022" report to their offering. During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson's (J&J's) Simponi and Takeda's Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively. Pfizer developed Xeljanz (tofacitinib, formerly known as tasocitinib), an oral, small-molecule JAK inhibitor, for the treatment of RA, and as a potential treatment for psoriasis, psoriatic arthritis, ankylosing spondylitis, CD, and UC. Xeljanz is a potential first-in-class product for UC, being one of the most advanced JAK inhibitors in the pipeline. Scope - Overview of Ulcerative Colitis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Xeljanz including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Xeljanz for the top eight countries from 2012 to 2022. - Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Canada. Reasons to buy - Understand and capitalize by identifying products that are most likely to ensure a robust return - Stay ahead of the competition by understanding the changing competitive landscape for Ulcerative Colitis - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential - Make more informed business decisions from insightful and in-depth analysis of Xeljanz performance Key Topics Covered: 1 Table of Contents 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Opportunity and Unmet Need 7 Pipeline Assessment 8 Xeljanz (tofacitinib) 9 Appendix For more information visit http://www.researchandmarkets.com/research/wbxt4m/xeljanz
Janssen Announces Expanded Collaboration with International Partnership for Microbicides for Development and Commercialization of Dapivirine for Prevention of Sexual Transmission of HIV
PR Newswire Europe - Thu May 08, 5:18AM CDT
-- Latest innovative collaboration from the Janssen Global Public Health group and significant contribution to Johnson & Johnson's wider efforts to improve public health worldwide
Johnson & Johnson Is Rewarding but Too Expensive
at The Street - Thu May 08, 5:00AM CDT
The share price may be too high for yield-hungry investors. But that could be changing soon.
Refractory Multiple Myeloma - Pipeline Review, H1 2014: 33 Companies and 48 Drugs Profiled
M2 - Thu May 08, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r636v2/refractory) has announced the addition of the "Refractory Multiple Myeloma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Refractory Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Multiple Myeloma and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Refractory Multiple Myeloma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Refractory Multiple Myeloma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Refractory Multiple Myeloma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved: - AbbVie Inc. - Acceleron Pharma, Inc. - Acetylon Pharmaceuticals, Inc. - Altor BioScience Corporation - Array BioPharma Inc. - Astellas Pharma Inc. - Bristol-Myers Squibb Company - Celgene Corporation - Eli Lilly and Company - Exelixis, Inc. - Genentech, Inc. - GlaxoSmithKline plc - Incyte Corporation - Janssen Biotech, Inc. - Johnson & Johnson - Kyowa Hakko Kirin Co., Ltd. - Millennium Pharmaceuticals, Inc. - MorphoSys AG - Novartis AG - Oncolytics Biotech Inc. - Oncopeptides AB - Onyx Pharmaceuticals, Inc. - Pfizer Inc. - Pharma Mar, S.A. - Pharmacyclics, Inc. - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Sanofi - Senesco Technologies, Inc. - Senhwa Biosciences Drug Profiles: - ixazomib citrate - panobinostat - carfilzomib - elotuzumab - plitidepsin - bendamustine - ibrutinib - ruxolitinib phosphate - ARRY-520 - ALT-801 - pomalidomide - chloroquine [bortezomib] [cyclophosphamide] - Melflufen - Circularly Permuted TRAIL - alisertib - daratumumab - PRLX-93936 - carfilzomib - cabozantinib (s)-malate - SNS-01T - SL-401 - TH-302 - P-276 - MOR-202 - KW-2478 - palbociclib - luminespib - plerixafor - ricolinostat - LY-2812176 For more information visit http://www.researchandmarkets.com/research/r636v2/refractory
Tuberculosis - Pipeline Review, H1 2014: 54 Companies and 141 Drugs Profiled
M2 - Thu May 08, 4:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gtc5l6/tuberculosis) has announced the addition of the "Tuberculosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Tuberculosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tuberculosis and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Tuberculosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Tuberculosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Tuberculosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved: - Abera Bioscience AB - Achillion Pharmaceuticals, Inc. - Anacor Pharmaceuticals, Inc. - Archivel Farma S.L. - AstraZeneca PLC - B&C Biopharm - BioDiem Ltd - Bioversys AG - Canopus BioPharma Incorporated - Cellceutix Corporation - Chimerix, Inc. - Chongqing Zhifei Biological Products Co., Ltd. - Crucell N.V. - Dafra Pharma International Ltd. - Eisai Co., Ltd. - Eli Lilly and Company - Ensoltek Co., Ltd. - EpiVax, Inc. - FIT Biotech Oyj - Genticel - GlaxoSmithKline plc - GlobalAcorn - Globeimmune, Inc. - Imaxio - Immunitor, Inc. - ImmunoBiology Ltd. - Immunovaccine, Inc. - Johnson & Johnson - Lipotek Pty Ltd. - Medisyn Technologies, Inc. Drug Profiles: - delamanid - delamanid - V-7 Vaccine - SQ-109 - delamanid - Tuberculosis Vaccine - sutezolid - VPM-1002 - GSK-692342 - Crucell Ad-35 - RUTI Vaccine - SSI H56-IC31 Vaccine - AERAS-422 Vaccine - IMX-313-TB - Ad5Ag85A Vaccine - PMX-10072 - NasL3/HtkBCG Vaccine - MTBVAC01 - Ac2SGL Diacylated Sulfoglycolipid Vaccine - HG-85A/B - HG856-A - HG856-BCG - R32Kda-BCG Vaccine - AERAS-Capsid Vaccine - HBHA Vaccine - Streptomyces Live Vector Vaccine - rBCG(mbtB)30 Vaccine - NasL3/AM85B Vaccine - paBCG Vaccine - ORT-VAC DNA Vaccine For more information visit http://www.researchandmarkets.com/research/gt...berculosis
Bone Metastasis - Pipeline Review, H1 2014: 20 Companies and 33 Drugs Profiled
M2 - Thu May 08, 3:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7v66kz/bone_metastasis) has announced the addition of the "Bone Metastasis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Metastasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Metastasis and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Bone Metastasis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Bone Metastasis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Bone Metastasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects Companies Involved: - APT Therapeutics, Inc. - Alethia Biotherapeutics Inc. - AlphaMab Co., Ltd - Amgen Inc. - Amura Holdings Ltd. - Bayer AG - Celsion Corporation - Debiopharm International S.A. - Deciphera Pharmaceuticals, LLC - DexTech Medical AB - Digna Biotech, S.L. - Eli Lilly and Company - Johnson & Johnson - Medivir AB - Merrion Pharmaceuticals Plc - Osteologix Holdings Plc. - Sigma-Tau S.p.A. - TWi Pharmaceuticals, Inc. - Takeda Pharmaceutical Company Limited - Transgene SA Drug Profiles: - denosumab - denosumab - radium Ra 223 dichloride - zoledronic acid - MLN-1202 - doxorubicin liposomal - radium Ra 223 dichloride - Osteodex - MIV-711 - Debio-0719 - P-17 - disitertide - MIV-710 - SST-0001 - TG-3003 - AB-25E9 - AM-3701 - DCC-2909 - AC-301 - APT-102 - Secreted Phosphoprotein 24 KDa - Vicrostatin - ADM-01 - JNJ-28312141 - DP-6865 - LY-2109761 - LY-364937 - EGFR Inhibitors for Oncology - (paclitaxel PEG alendronate) For more information visit http://www.researchandmarkets.com/research/7v...metastasis
